May 11, 2020
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Feb 10, 2020
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020
Feb 10, 2020
Takeda to Present Research Advances in Rare Lysosomal Storage Disorders at 16th Annual WORLDSymposium(TM) 2020
Feb 06, 2020
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
Jan 30, 2020
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium(TM) 2020
Nov 27, 2019
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease
Nov 18, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Nov 07, 2019
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
Sep 24, 2019
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
Feb 20, 2019
Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease
Feb 14, 2019
Global Fabry Disease Market Insights, Epidemiology and Market Report 2019
Aug 10, 2018
FDA approves new treatment for a rare genetic disorder, Fabry disease
Aug 03, 2017
Lysosomal Storage Disorder Therapeutics Pipeline Analysis 2017